Indication expansion

Longevity-extending compounds key to neurodegenerative treatment

Compounds found to increase lifespan in animal models could hold the key to treatments for debilitating neurodegenerative conditions such as Alzheimer’s and Parkinson’s disease.  Neurodegenerative...

The metformin debate swings both ways

Research on metformin is not at the beginning of the end, but it is, perhaps, at the end of the beginning. The drug giveth and...

$2m Longevity boost for rapamycin Alzheimer’s study

Rapamycin human clinical trial aims to make progress on Alzheimer's therapy. A new $2m grant will enable a clinical trial to examine the effects of...

GlobalData finds AI accelerates drug repurposing

GlobalData says AI holds significant promise for biopharmaceutical companies to expedite the drug repurposing process. Artificial intelligence is the go-to engine for research breakthroughs. Applying...

FDA approval for small molecule drug bodes well for Longevity

Roche, the world’s largest biotech company, has won approval from the FDA for an SMA drug. The race to take a therapy from lab to...

Fruit fly research could hold key to lifespan

Research carried out on the effects of the drug Mifepristone on fruit flies and roundworms has revealed key findings that could pave the way...

Exploring the neuroprotective benefits of Longevity drug candidates

Understanding the role aging plays in neurodegenerative diseases could be the key to curing them – or even preventing them with neuroprotective candidates. A team...

Challenging the one drug/one disease model

A new paper supports the targeting of aging processes, rather than just one disease, to improve Longevity outcomes. Multimorbidity is a challenge for Longevity; defined...

Fountain’s ‘hypothesis-free’ approach to Longevity AI

We reached out to Fountain’s CEO John Dimos to see what more we can learn about the mysterious San Francisco start-up. When it comes to...

Applying theoretical physics to Longevity drug discovery

Peter Fedichev's Gero raising $10 million for anti-aging drug discovery and clinical trials. The use of AI in Longevity drug discovery is nothing new, Insilico...

Longevity and the art of motorcycle maintenance

OpenCures' Kevin Perrott talks about empowering the consumer with their own health data. One of the Longevity sector’s leading voices came to the field relatively...

Longevity2020: Day 5 Recap

On Friday, the Longevity2020 online conference drew to a close, and the final day explored what people can be doing today to address their...

BioAge licenses HIF-PH inhibitor to treat aging

BioAge's human aging data platform demonstrates that HIF pathway is linked to healthspan and lifespan. Longevity focused biotech firm BioAge Labs has announced an exclusive...

Longevity2020: Day 3 recap

Experts, innovators, investors and the curious meet online in the biggest Longevity conference ever staged. As we enter the fourth day of Longevity2020, we thought...

Longevity2020: Day 2 recap

Yesterday at Longevity2020 was all about rejuvenation therapies, bringing together some of the world’s leading luminaries in the fight against aging. Things kicked off with...

Building faster and better age-related clinical trials

Prof Ilaria Bellantuono seeks to build faster, better clinical trials for age-related disease with a focus on frailty. Multimorbidity – an individual suffering two or...

COVID-19: Leading clinician calls for focus on the biology of aging

Dr Nir Barzilai predicts that rapamycin could decrease severity of coronavirus in the elderly by 50%. Longevity.Technology: When it comes to the world of Longevity...

Join me at my 100th birthday party in 2049!

We speak with GRG's Johnny Adams, a key contributor to the Longevity2020 online conference, about his quest for more healthy years. Longevity.Technology: The curator on Thursday 30th April...

Low-dose rapamycin to protect elderly from COVID-19

Longevity researcher proposes clinical trials for low-dose rapamycin (and other geroprotectors) to protect the elderly from COVID-19. The UK's Biogerontology Research Foundation today announced the...

Chemical screening to find hidden Longevity gems?

Start-up NemaLife evolves from platform technology to services provider to identify chemicals that have both positive and negative effects on Longevity. The use of the...

Latest articles

Epigenetic regulation of protein homeostasis following DNA damage

Recent study identifies critical regulator of protein biosynthesis recovery and homeostasis required for Longevity. Unresolved DNA damage caused by intrinsic and environmental factors accumulates during...

Deep Longevity and Longenesis collaborate to clock aging

Start the clock to stop the clock – centralised data will aid Longevity research.  Deep Longevity, which engages in the development of explainable AI systems...

Big Brother approach to accelerate preclinical studies

Tracked.bio develops AI computer vision system that tracks flies and mice to reduce man-hours and increase data collected in Longevity studies. A Danish start-up aims...

Astellas to acquire iota Biosciences

Following an R&D collaboration that began last year, Japanese pharma Astellas has announced it will acquire bioelectronics firm iota in $304m deal. Last year's R&D...